Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study von Montalban, Xavier, Leist, Thomas P, Cohen, Bruce A, Moses, Harold, Campbell, Jackie, Hicking, Christine, Dangond, Fernando, Comi, Giancarlo, Gallo, Paolo, Pozzilli, Carlo, Gasperini, Claudio, Morra, Vincenzo Brescia, Boyko, Alexey N, Amelina, Olga, Kotov, Sergey V, Novikova, Lilia, Patrusheva, Olga, Zavalishin, Igor, Khabirov, Farid, Maslova, Natalia, Malkova, Nadezda, Poverennova, Irina E, Montalban, Xavier, Martinez Yelamos, Sergio, Izquierdo, Guillermo, Fernandez, Oscar, Rodriguez-Antiguedad, Alfredo, Sempere, Angel Perez, Arroyo, Rafael, Casanova, Bonaventura, Arias, Manual, Cascione, Mark, Cohen, Bruce Arnold, Fox, Edward, Berkovich, Regina, Kaufman, Michael, Leist, Thomas, Jacobs, Dina, Miller, Tamara, Racke, Michael, Hutton, George, Singer, Barry, Kresa-Reahl, Kiren, Pharr, Emily, Carter, Jonathan L, Wendt, Jeanette, Tandan, Rup, Bomprezzi, Roberto, Ford, Corey, Kamin, Stephen, Pless, Misha, Garmany, George P, Gazda, Suzanne, English, Jeffrey, Green, Barbara, Garwacki, Dennis, Gould, Jeffrey, LaGanke, Chris

Volltext

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial von Comi, Giancarlo, Kappos, Ludwig, Selmaj, Krzysztof W, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans-Peter, Montalban, Xavier, Kubala Havrdová, Eva, Cree, Bruce A C, Sheffield, James K, Minton, Neil, Raghupathi, Kartik, Ding, Ning, Cohen, Jeffrey A

Volltext

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial von Cohen, Jeffrey A, Comi, Giancarlo, Selmaj, Krzysztof W, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans-Peter, Montalban, Xavier, Kubala Havrdová, Eva, Cree, Bruce A C, Sheffield, James K, Minton, Neil, Raghupathi, Kartik, Huang, Vivian, Kappos, Ludwig

Volltext

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial von Sims, John R, Zimmer, Jennifer A, Evans, Cynthia D, Lu, Ming, Ardayfio, Paul, Sparks, JonDavid, Wessels, Alette M, Shcherbinin, Sergey, Wang, Hong, Monkul Nery, Emel Serap, Collins, Emily C, Solomon, Paul, Salloway, Stephen, Apostolova, Liana G, Hansson, Oskar, Ritchie, Craig, Brooks, Dawn A, Mintun, Mark, Skovronsky, Daniel M

Volltext

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention von Yeh, Robert W, Secemsky, Eric A, Kereiakes, Dean J, Normand, Sharon-Lise T, Gershlick, Anthony H, Cohen, David J, Spertus, John A, Steg, Philippe Gabriel, Cutlip, Donald E, Rinaldi, Michael J, Camenzind, Edoardo, Wijns, William, Apruzzese, Patricia K, Song, Yang, Massaro, Joseph M, Mauri, Laura

Volltext

Endovascular Treatment for Acute Ischemic Stroke von Kaijser, Magnus, Andersson, Tommy, Gakuba, Clement, Gauberti, Maxime, Vivien, Denis, Arnold, Marcel, Schroth, Gerhard, Gralla, Jan, Campbell, Bruce C, Donnan, Geoffrey A, Davis, Stephen M, Cohen, José E, Leker, Ronen R, Broderick, Joseph P, Tomsick, Thomas A, Palesch, Yuko Y, Ciccone, Alfonso, Valvassori, Luca, Kidwell, Chelsea S, Jahan, Reza, Saver, Jeffrey L

Volltext

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials von Harris, Sarah, Comi, Giancarlo, Cree, Bruce A. C., Arnold, Douglas L., Steinman, Lawrence, Sheffield, James K., Southworth, Harry, Kappos, Ludwig, Cohen, Jeffrey A.

Volltext

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial von Cree, Bruce AC, Selmaj, Krzysztof W, Steinman, Lawrence, Comi, Giancarlo, Bar-Or, Amit, Arnold, Douglas L, Hartung, Hans-Peter, Montalbán, Xavier, Havrdová, Eva K, Sheffield, James K, Minton, Neil, Cheng, Chun-Yen, Silva, Diego, Kappos, Ludwig, Cohen, Jeffrey A

Volltext

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study von Cohen, Jeffrey A, Comi, Giancarlo, Arnold, Douglas L, Bar-Or, Amit, Selmaj, Krzysztof W, Steinman, Lawrence, Havrdová, Eva K, Cree, Bruce AC, Montalbán, Xavier, Hartung, Hans-Peter, Huang, Vivian, Frohna, Paul, Skolnick, Brett E, Kappos, Ludwig

Volltext

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study von Florian, Hana, Wang, Deli, Arnold, Steven E, Boada, Mercè, Guo, Qi, Jin, Ziyi, Zheng, Hui, Fisseha, Nahome, Kalluri, Hari Varun, Rendenbach-Mueller, Beatrice, Budur, Kumar, Gold, Michael

Volltext

Neurosurgical Implant Safety in 7 T MRI: A Scoping Review von Shaffer, Annabelle, Weisbaum, David, Naik, Anant, Anderson, Aaron, Wszalek, Tracey, Cohen, Mark, Sutton, Brad, Webb, Andrew, Damon, Bruce, Arnold, Paul M.

Volltext

Phase 2 of CATALISE: a multinational and multidisciplinary Delphi consensus study of problems with language development: Terminology von Bishop, Dorothy V.M., Snowling, Margaret J., Thompson, Paul A., Greenhalgh, Trisha, Adams, Catherine, Archibald, Lisa, Baird, Gillian, Bauer, Ann, Bellair, Jude, Boyle, Christopher, Brownlie, Elizabeth, Carter, Glenn, Clark, Becky, Clegg, Judy, Cohen, Nancy, Conti‐Ramsden, Gina, Dockrell, Julie, Dunn, Janet, Ebbels, Susan, Gallagher, Aoife, Gibbs, Simon, Gore‐Langton, Emma, Grist, Mandy, Hartshorne, Mary, Hüneke, Alison, Joanisse, Marc, Kedge, Sally, Klee, Thomas, Krishnan, Saloni, Lascelles, Linda, Law, James, Leonard, Laurence, Lynham, Stephanie, Arnold, Elina Mainela, Mathura, Narad, McCartney, Elspeth, McKean, Cristina, McNeill, Brigid, Morgan, Angela, Murphy, Carol‐Anne, Norbury, Courtenay, O'Hare, Anne, Cardy, Janis Oram, O'Toole, Ciara, Paul, Rhea, Purdy, Suzanne, Redmond, Sean, Restrepo, Laida, Rice, Mabel, Slonims, Vicky, Snow, Pamela, Speake, Jane, Spencer, Sarah, Stringer, Helen, Tager‐Flusberg, Helen, Tannock, Rosemary, Taylor, Cate, Tomblin, Bruce, Volden, Joanne, Westerveld, Marleen, house, Andrew

Volltext

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis von Fox, Robert J, Coffey, Christopher S, Conwit, Robin, Cudkowicz, Merit E, Gleason, Trevis, Goodman, Andrew, Klawiter, Eric C, Matsuda, Kazuko, McGovern, Michelle, Naismith, Robert T, Ashokkumar, Akshata, Barnes, Janel, Ecklund, Dixie, Klingner, Elizabeth, Koepp, Maxine, Long, Jeffrey D, Natarajan, Sneha, Thornell, Brenda, Yankey, Jon, Bermel, Robert A, Debbins, Josef P, Huang, Xuemei, Jagodnik, Patricia, Lowe, Mark J, Nakamura, Kunio, Narayanan, Sridar, Sakaie, Ken E, Thoomukuntla, Bhaskar, Zhou, Xiaopeng, Krieger, Stephen, Alvarez, Enrique, Apperson, Michelle, Bashir, Khurram, Cohen, Bruce A, Coyle, Patricia K, Delgado, Silvia, Dewitt, L. Dana, Flores, Angela, Giesser, Barbara S, Goldman, Myla D, Jubelt, Burk, Lava, Neil, Lynch, Sharon G, Moses, Harold, Ontaneda, Daniel, Perumal, Jai S, Racke, Michael, Repovic, Pavle, Riley, Claire S, Severson, Christopher, Shinnar, Shlomo, Suski, Valerie, Weinstock-Guttman, Bianca, Yadav, Vijayshree, Zabeti, Aram

Volltext

Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS von DeLuca, John, Schippling, Sven, Montalban, Xavier, Kappos, Ludwig, Cree, Bruce A.C., Comi, Giancarlo, Arnold, Douglas L., Hartung, Hans-Peter, Sheffield, James K., Liu, Hongjuan, Silva, Diego, Cohen, Jeffrey A.

Volltext

Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program von Selmaj, Krzysztof W., Cohen, Jeffrey A, Comi, Giancarlo, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans Peter, Montalban, Xavier, Havrdova, Eva Kubala, Cree, Bruce A.C., Minton, Neil, Sheffield, James K, Ding, Ning, Kappos, Ludwig

Volltext

Review of the National Ignition Campaign 2009-2012 von Lindl, John, Landen, Otto, Edwards, John, Moses, Ed

Volltext

Long-term Efficacy of the Sphingosine 1-Phosphate Receptor Modulator Ozanimod by Age Category in Patients with Relapsing Multiple Sclerosis: Final Results from Two Phase 3 Trials a... von Steinman, Lawrence, Selmaj, Krzysztof, Comi, Giancarlo, Bar-Or, Amit, Arnold, Douglas, Hartung, Hans-Peter, Montalban, Xavier, Havrdova, Eva, Sheffield, James, Cheng, Chun-Yen, Reardon, Jennifer, Riolo, Jon, Deboer, Erik, Kappos, Ludwig, Cohen, Jeffrey, Cree, Bruce

Volltext

Impact of ozanimod treatment on cortical grey matter volume: up to 5 years’ experience in phase 3 and extension trials (P5-4.005) von Pachai, Chahin, Sheffield, James, Montalban, Xavier, Cree, Bruce, Kappos, Ludwig, Comi, Giancarlo, Hartung, Hans-Peter, Cheng, Chun-Yen, Silva, Diego, Cohen, Jeffrey, Arnold, Douglas

Volltext

Molecular and clinical genetics of mitochondrial diseases due to POLG mutations von Wong, Lee-Jun C, Naviaux, Robert K, Brunetti-Pierri, Nicola, Zhang, Qing, Schmitt, Eric S, Truong, Cavatina, Milone, Margherita, Cohen, Bruce H, Wical, Beverly, Ganesh, Jaya, Basinger, Alice A, Burton, Barbara K, Swoboda, Kathryn, Gilbert, Donald L, Vanderver, Adeline, Saneto, Russell P, Maranda, Bruno, Arnold, Georgianne, Abdenur, Jose E, Waters, Paula J, Copeland, William C

Volltext

Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010) von Arnold, Douglas L., Freeman, Leorah, Hartung, Hans-Peter, Montalbán, Xavier, Cohen, Jeffrey A., Bar-Or, Amit, Steinman, Lawrence, DeLuca, John, Cheng, Chun-Yen, Riolo, Jon V., Silva, Diego, Pachai, Chahin, Cree, Bruce A. C.

Volltext